27/08/08
Oralair® Grasses 300 IR : Highly positive results in a pharmacodynamic study conducted in an allergen challenge chamber
Stallergenes S.A. announces the highly positive results of a new study conducted in an Allergen Challenge Chamber (ACC).
The study on Oralair® Grasses included 86 adult patients exposed to grass pollen challenge with different...
27/08/08
First Half Year 2008: a 19% increase in operating profit and net profit
The Board of Directors, meeting today under the chairmanship of Albert Saporta, approved Stallergenes' half year consolidated financal statements:
10/07/08
Q2 2008 sales up 18%
1st half-year sales up 16%, revision upwards of 2008 sales growth guidance: ≥12%
24/06/08
Obtention of the market authorization in Germany for Oralair® Grasses
Stallergenes has been granted with the market authorization in Germany for its sublingual desensitisation tablet Oralair® Grasses.
12/03/08
2007 results
Further profit growth; Sales up 16%; Profit before R&D up 19%;
Net profit (Group share) up 12%; Acceleration of R&D expenditure
10/01/08
Implementation of a liquidity contract
Stallergenes has entrusted SG Securities Paris with the implementation of a liquidity contract
